|
Compared to hydroxyurea, treatment with interferon-alpha (IFN-alpha) is
known to prolong survival in patients with chronic phase of chronic myelogenous
leukaemia (CML) and was considered as first-line therapy till recently. We
conducted a multicentre trial using an indigenous recombinant IFN-alpha-2b to
evaluate its efficacy and toxicity in chronic phase CML. METHODS: Between
September 2000 and August 2001, patients with chronic phase CML were recruited
within 8 weeks of diagnosis at 7 centres in India. The study was approved by the
Ethics Committee of each participating Institute and Informed, written consent
was obtained from all patients. All patients were given the study drug in a dose
of 5 million units daily subcutaneously.
|
[CML] A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com
